Date: 2016-07-11
Type of information: Nomination
Compound:
Company: Ipsen (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 11, 2016, Ipsen announced that the Board of Directors of Ipsen has appointed David Meek as Chief Executive Officer, effective July 18,2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the Board of Directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.
David Meek, an American national, has over 25 years of experience in the pharmaceutical industry where he held various global executive positions in major pharmaceutical and biotechnology companies. Most recently, he was Executive Vice-President and President of the oncology division of Baxalta Inc., which was recently acquired by Shire. David led the formation of the oncology division and rapidly created an innovative oncology portfolio through strategic acquisitions and partnering deals.
David Meek holds a BA in Management from the University of Cincinnati and started his career at Johnson & Johnson and Janssen Pharmaceutica (1989-2004) where he held a variety of U.S. senior sales and marketing positions across multiple therapeutic areas in primary care (gastroenterology, pain management, dermatology) and specialty care (oncology, neuroscience). He then joined Novartis (2005-2012), where he successively served as the global businessfranchise head for the company’s respiratory and dermatology franchise in Basel, Switzerland; President and Chief Executive Officer of the pharmaceutical division in Canada; and the head of
oncology for Northern, Central and Eastern Europe, based in Milan, Italy. From 2012 to 2014, he served as Chief Commercial Officer of Endocyte, an American biotechnology company.
David Meek will be based at Ipsen’s headquarters in Boulogne-Billancourt. His mission is to ensure the continued growth and innovative pipeline development of the specialty and primary care businesses and to advance the international expansion of the Ipsen Group especially in the United States and China.
Financial terms:
Latest news:
